Ridgetech, Inc. (RDGT) Fair Value 2026

RDGT · Retail-Drug Stores and Proprietary Stores ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.5 /10

32 fundamental signals · 9 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-14, Ridgetech, Inc. (RDGT) trades at $1.61, approximately 339% above CirclFi’s Bayesian DCF fair value of $0.37. QOC: 2.5/10. 9/13 models active.

Key Facts

Ticker
RDGT
Price
$1.61
Quality Score
2.5/10
Value Trap Risk
—/100
Models Active
9/13
Last Updated
Strength: Earnings Power Value suggests +290.7% upside with 22% confidence
Risk: Below-average Quality Score of 2.5/10 signals weak fundamentals

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($1.61)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.37 -77.2%
Earnings Power Value
Medium Conviction
$6.29 +290.7%
First Chicago
Low Conviction
$1.39 -13.8%
Dynamic NAV
Medium Conviction
$2.64 +63.7%

Unlock the Full Matrix

Access 5 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Ridgetech, Inc. (RDGT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Ridgetech, Inc.'s intrinsic value is estimated at $2.66, suggesting a +65.4% average upside from the current price of $1.61. While 5 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: EPV targets $6.29 (+290.7%), versus Bayesian DCF at $0.37 (-77.2%). This +367.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About RDGT?

9 of 13 models are currently active for RDGT. Of these, 5 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates RDGT's intrinsic value at $0.37, implying -77.2% downside from the current price. See which stocks rank higher →

How Does RDGT Rank in Retail-Drug Stores and Proprietary Stores?

Among 5 Retail-Drug Stores and Proprietary Stores stocks, RDGT ranks #5 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.

As a biopharma enterprise, Ridgetech, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating RDGT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RDGT a Value Trap?

The Value Trap algorithm is not active for RDGT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Ridgetech, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Ridgetech, Inc.'s fundamental quality profile registers 2.5/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +367.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RDGT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RDGT's 9 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Ridgetech, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Retail-Drug Stores and Proprietary Stores Stocks Should You Also Analyze?

4 related Retail-Drug Stores and Proprietary Stores stocks with 13-model coverage

Read investment analysis: CVS · YI · GRDN · PETS

Frequently Asked Questions About Ridgetech, Inc.

What is Ridgetech, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Ridgetech, Inc. (RDGT) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.37. The Quality of Company score is 2.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RDGT overvalued or undervalued right now?

At $1.61, 5 of 9 active models suggest RDGT may be undervalued, while 4 indicate potential overvaluation. The assessment depends on which methodology best fits Ridgetech, Inc.'s business model in Retail-Drug Stores and Proprietary Stores.

What does a Quality of Company score of 2.5 mean for RDGT?

Ridgetech, Inc.'s QOC of 2.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RDGT?

CirclFi analyzes RDGT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is RDGT a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for RDGT at this time. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on RDGT.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access